Abstracts tagged "neutrophils"

Abstract Number: 0665 • ACR Convergence 2025
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard Furie¹, Teresa Baczkowska², Amit Saxena³, Imran Hassan⁴, Bongin Yoo⁵, Ben Lanza⁶, Himanshi Sehgal⁷, Frederic Boissard⁷, Jay Garg⁵, Thomas Schindler⁷, Elsa Martins⁷, William Pendergraft⁵ and Brad Rovin⁸, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸The Ohio State University, Columbus, OH
Background/Purpose: The REGENCY (NCT04221477) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus…
Abstract Number: 2231 • ACR Convergence 2025
Inverse Correlation Between Neutrophil Activation and Rheumatoid Factor Concentrations in Rheumatoid Arthritis (RA)
Anne-Christine Bay-Jensen¹, Dovile Sinkeviciute², Christian Thudium², shu Sun¹, Mathilde Christensen¹, Morten Karsdal¹, marta Alexdottir¹ and Joachim mortensen¹, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Neutrophils are crucial in fibro-inflammatory diseases like Crohn's disease (CD) and rheumatoid arthritis (RA), but their biomarkers are better established in CD than in…
Abstract Number: 0609 • ACR Convergence 2025
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Eleni Papachristodoulou¹ and Vasileios Kyttaris², ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…
Abstract Number: 2078 • ACR Convergence 2025
Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells
Yatzil Reyna Juárez¹, Jennifer Tiaré Balderas Miranda², Beatriz Alcalá Carmona³, María José Ostos Prado⁴, karina santana⁵, Diana Gómez-Martín⁶ and Jiram Torres Ruiz⁷, ¹Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ²Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ³INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Ciudad de México, Federal District, Mexico, ⁶INCMNSZ, Mexico city, Federal District, Mexico, ⁷INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: Dermatomyositis (DM) and anti-synthetase syndrome (AS) are idiopathic inflammatory myopathies (IIM) with perifascicular pathology involving vasculopathy, macrophages, dendritic cells and an overexpression of interferon-stimulated…
Abstract Number: 0857 • ACR Convergence 2025
CD14-dependent MAP kinase signaling is required for pathogenic neutrophil extracellular trap formation in APS
Thalia Newman¹, NaveenKumar Somanathapura¹, Chao Liu², Srilakshmi Yalavarthi¹, Pooja Kapoor¹, Ajay Tambralli¹, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Superior Charter Twp, MI
Background/Purpose: Antibodies targeting beta-2-glycoprotein I (anti-β2GPI) promote inflammation and thrombosis in antiphospholipid syndrome (APS). It has been shown that anti-β2GPI activate neutrophils through Toll-like receptor…
Abstract Number: 2052 • ACR Convergence 2025
Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.
Agustin Hernández-López¹, Nancy R Mejía Domínguez², Yatzil Reyna Juárez³, María José Ostos Prado⁴, Beatriz Alcalá Carmona⁵, Jennifer Tiaré Balderas Miranda⁶, Carlos A. Núñez-Álvarez⁵, Marta E. Baños-Laredo⁷, Álvaro Abiel Sierra-Salazar⁵, Johan Camacho-Pérez⁵, Marco Aurelio Martínez-Rivera⁵, Diana Gómez-Martín⁸ and Jiram Torres-Ruiz⁹, ¹Instituo Nacional de Ciencias Médicas y Nutricion Salvador Zubirán, Morelia, Michoacan de Ocampo, Mexico, ²Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ³Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁶Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁷INCMNSZ, Cdmx, Mexico, ⁸INCMNSZ, Mexico city, Federal District, Mexico, ⁹INCMNSZ, Ciudad de México, Mexico
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have increased production and decreased clearance of neutrophil extracellular traps (NETs), which may promote the production of anti-NETs…
Abstract Number: 0859 • ACR Convergence 2025
Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
Bruna Mazetto Fonseca¹, Srilakshmi Yalavarthi², Katarina Kmetova², NaveenKumar Somanathapura³, Cyrus Sarosh⁴, Kavya Sugur⁵, Wenying Liang⁶, Yu (Ray) Zuo³, Richard W. Lieberman⁶ and Jason S. Knight³, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ³University of Michigan, Ann arbor, MI, ⁴University of Michigan, Temperance, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁶University of Michigan, Ann arbor
Background/Purpose: Neutrophil extracellular traps (NETs) are webs of chromatin and proteases (e.g., neutrophil elastase) that have been implicated in antiphospholipid syndrome (APS)-associated thrombosis; however, their…
Abstract Number: 1874 • ACR Convergence 2025
Neutrophil Extracellular Trap-Rich Systemic Sclerosis Plasma Promotes Microvascular Endothelial Cell Proliferation and Migration: Implications for Aberrant Angiogenesis
Wenying Liang¹, James St. Clair¹, Pei-Suen Tsou², John Varga², Jason S. Knight², Dinesh Khanna² and Ramadan Ali³, ¹University of Michigan, Ann arbor, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arobr, MI
Background/Purpose: Systemic sclerosis (SSc, also known as scleroderma) is a systemic disease characterized by fibrosis, autoimmunity, and vasculopathy. Neutrophil extracellular traps (NETs) are web‐like chromatin…
Abstract Number: 0723 • ACR Convergence 2025
Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Michele Moretti¹, Francesco Ferro², Francesco Pisani³, Elisa Ferrigno³, Gaetano La Rocca⁴, Federica Di Cianni⁵, Rosaria Talarico⁶, Marta Mosca⁷, Chiara Baldini⁷ and Ilaria Puxeddu³, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁵Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: EGPA variably presents eosinophil (EOS)-related features and vasculitic manifestations. Recent introduction of mepolizumab (MEP) has revolutionized the treatment of EOS manifestations of EGPA. However,…
Abstract Number: 1843 • ACR Convergence 2025
Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Norio Hanata¹, Carmelo Carmona-Rivera¹, Victoria Hoffman², Kan Jiang³, davide Randazzo⁴, Meryl Waldman⁵, Sarfaraz Hasni⁶ and Mariana Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ³Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Bethesda, PA, ⁶National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease that frequently affects the kidneys, with lupus nephritis (LN) being a major contributor to morbidity…
Abstract Number: 0493 • ACR Convergence 2025
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Maarten Kraan¹, Salah Hadi², Leonie Middelink³, Renato Chirivi³, Eric meldrum³, Naomi Klarenbeek⁴ and Patrick Round³, ¹Citryll BV, Den Dolder, Netherlands, ²ICON Netherlands BV, Groningen, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…
Abstract Number: 1814 • ACR Convergence 2025
Trapped in the NET: Impaired DNase function and targeted antibodies in the pathogenesis of pediatric lupus nephritis
Sohei Makita¹, Joyce Hui-Yuen², Bharati Matta³, Betsy Barnes⁴, Jenna Battaglia⁵, Tatiana Borja⁶, Boris Reizis⁷, Lydia Thomas⁸ and Kim Simpfendorfer⁹, ¹NYU, New York, ²North Shore LIJ Health System, Great Neck, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Northwell Health, Manhasset, NY, ⁵Northwell Health, Manhasset, ⁶Northwell Health- Cohen Children’s Medical Center, Elmhurst, NY, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ⁹Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Up to 80% of patients with pediatric systemic lupus erythematosus (pSLE) can present with renal abnormalities. Treatment of pSLE is often difficult and includes…
Abstract Number: 0486 • ACR Convergence 2025
Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Hideto Kameda¹, Sadatomo Tasaka², Toshiya Takahashi³, Naoki Soeda³, Katsuhisa Suzuki⁴ and Yoshiya Tanaka⁵, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ⁴Medical Affairs, Sanofi K.K., Tokyo, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Sarilumab (SAR) is approved as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for treatment of patients (pts) with moderate-to-severely active…
Abstract Number: 1623 • ACR Convergence 2025
The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
Katarina Kmetova¹, Gavin Poppei², Kavya Sugur³, Julia Ford⁴, Wenying Liang⁴, Emily Chong⁴, Srilakshmi Yalavarthi⁴, NaveenKumar Somanathapura⁴, Nataliya Milman⁵, Peter Merkel⁶, Ora Singer⁷ and Yu (Ray) Zuo⁴, ¹Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ²University of Michigan, Ann arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵the Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Michigan, Huntington Woods, MI
Background/Purpose: Clinically-isolated aortitis (CIA), defined as inflammation of the aortic wall in the absence of extra-aortic arterial involvement, systemic vasculitis, or other associated autoimmune disease,…
Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Sangeeta Kumari¹, Eric meldrum¹, Josephine Stein¹, Tirza Bruurmijn¹, Robin de Jong², Katerina Pardali¹, Maarten Kraan¹, Renato Chirivi¹, Rogier Thurlings³ and Michael Nurmohamed², ¹Citryll BV, Oss, Netherlands, ²Reade, Amsterdam, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].